Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. by Un, Keita et al.
Title Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy.
Author(s)Un, Keita; Kawakami, Shigeru; Suzuki, Ryo; Maruyama,Kazuo; Yamashita, Fumiyoshi; Hashida, Mitsuru
CitationBiomaterials (2010), 31(30): 7813-7826
Issue Date2010-10
URL http://hdl.handle.net/2433/126738




                             Elsevier Editorial System(tm) for Biomaterials 
                                  Manuscript Draft 
 
 
Manuscript Number: jbmt14306R1 
 
Title: Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine 
therapy  
 
Article Type: FLA Original Research 
 
Section/Category: Biomaterials & Gene Transfer 
 
Keywords: Gene transfer, Bubble lipoplexes, Ultrasound exposure, Mannose receptors, Antigen 
presenting cells, DNA vaccine therapy 
 
Corresponding Author: Dr. Mitsuru Hashida, Ph.D. 
 
Corresponding Author's Institution: Graduate School of Pharmaceutical Sciences, Kyoto University 
 
First Author: Keita Un 
 
Order of Authors: Keita Un; Shigeru Kawakami, Ph.D.; Ryo Suzuki, Ph.D.; Kazuo Maruyama, Ph.D.; 
Fumiyoshi Yamashita, Ph.D.; Mitsuru Hashida, Ph.D. 
 
Abstract: Development of a gene delivery system to transfer the gene of interest selectively and 
efficiently into targeted cells is essential for achievement of sufficient therapeutic effects by gene 
therapy.  Here, we succeeded in developing the gene transfection method using ultrasound (US)-
responsive and mannose-modified gene carriers, named Man-PEG2000 bubble lipoplexes.  Compared 
with the conventional lipofection method using mannose-modified carriers, this transfection method 
using Man-PEG2000 bubble lipoplexes and US exposure enabled approximately 500~800-fold higher 
gene expressions in the antigen presenting cells (APCs) selectively in vivo.  This enhanced gene 
expression was contributed by the improvement of delivering efficiency of nucleic acids to the targeted 
organs, and by the increase of introducing efficiency of nucleic acids into the cytoplasm followed by US 
exposure.  Moreover, high anti-tumor effects were demonstrated by applying this method to DNA 
vaccine therapy using ovalbumin (OVA)-expressing plasmid DNA (pDNA).  This US-responsive and cell-
specific gene delivery system can be widely applied to medical treatments such as vaccine therapy and 
anti-inflammation therapy, which its targeted cells are APCs, and our findings may help in establishing 
innovative methods for in-vivo gene delivery to overcome the poor introducing efficiency of carriers 
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Development of a gene delivery system to transfer the gene of interest selectively and 
efficiently into targeted cells is essential for achievement of sufficient therapeutic effects by 
gene therapy.  Here, we succeeded in developing the gene transfection method using 
ultrasound (US)-responsive and mannose-modified gene carriers, named Man-PEG2000 bubble 
lipoplexes.  Compared with the conventional lipofection method using mannose-modified 
carriers, this transfection method using Man-PEG2000 bubble lipoplexes and US exposure 
enabled approximately 500~800-fold higher gene expressions in the antigen presenting cells 
(APCs) selectively in vivo.  This enhanced gene expression was contributed by the 
improvement of delivering efficiency of nucleic acids to the targeted organs, and by the 
increase of introducing efficiency of nucleic acids into the cytoplasm followed by US 
exposure.  Moreover, high anti-tumor effects were demonstrated by applying this method to 
DNA vaccine therapy using ovalbumin (OVA)-expressing plasmid DNA (pDNA).  This 
US-responsive and cell-specific gene delivery system can be widely applied to medical 
treatments such as vaccine therapy and anti-inflammation therapy, which its targeted cells are 
APCs, and our findings may help in establishing innovative methods for in-vivo gene delivery 
to overcome the poor introducing efficiency of carriers into cytoplasm which the major 
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In the post-genome era, the analysis of disease-related genes has rapidly advanced, and 
the medical application of the information obtained from gene analysis is being put into 
practice.  In particular, the development of effective method to transfer the gene of interest 
selectively and efficiently into the targeted cells is essential for the gene therapy of refractory 
diseases, in-vivo functional analysis of genes and establishment of animal models for diseases.  
However, a suitable carrier for selective and efficient gene transfer to the targeted cells is still 
being developed.  Although various types of viral and non-viral carriers have been 
developed for gene transfer, they are limited to use by viral-associated pathogenesis and low 
transfection efficiency, respectively.  For the cell-selective gene transfer, many investigators 
have focused on ligand-modified non-viral carriers such as liposomes [1-4], emulsions [5], 
micelles [6] and polymers [7], because of their high productivity and low toxicity.  On the 
other hand, since the gene transfection efficiency by non-viral carriers is poor, it is difficult to 
obtain the effective therapeutic effects by gene therapy using non-viral carriers.  Moreover, 
in the gene transfection using conventional ligand-modified non-viral carriers, since the 
carriers need to be taken up into cells via endocytosis following by interaction with targeted 
molecules on the cell membrane, the number of candidates which are suitable as ligands for 
targeted gene delivery is limited. 
Some researchers have attempted to develop the transfection method using external 
stimulation, such as electrical energy [8], physical pressure [9] and water pressure [10], to 
enhance the gene transfection efficiency.  Among these, gene transfection method using US 
exposure and microbubbles enclosing US imaging gas, called “sonoporation method”, have 
been focused as effective drug/gene delivery systems [11-14].  In the sonoporation method, 




































































generated by the destruction of microbubbles.  Consequently, the transient pores are created 
on the cell membrane, and large amount of nucleic acids are directly introduced into the 
cytoplasm through the created pores [13,15,16].  However, the in-vivo gene transfection 
efficiency by conventional sonoporation method administering the nucleic acids and 
microbubbles separately is low because of the rapid degradation of nucleic acids in the body 
[17], the large particle size of conventional microbubbles [15] and the different 
pharmacokinetic profiles of the nucleic acids and microbubbles.  Moreover, to transfer the 
gene into the targeted cells selectively by sonoporation method in vivo, the control of in-vivo 
distribution of nucleic acids and microbubbles, which are separately administered, is 
necessary. 
In our previous report [16], we have demonstrated the effective transfection by 
combination-use method using our mannosylated lipoplexes composed of Man-C4-chol: 
DOPE [1], and conventional Bubble liposomes (BLs) [12] with US exposure.  However, this 
combination-use method is complicated because of the necessity for multiple injections of 
mannosylated lipoplexes and BLs; therefore, it is difficult to apply for medical treatments 
using multiple transfections.  In addition, the difference of in-vivo distribution 
characteristics between mannosylated lipoplexes and BLs might be decreased its transfection 
efficacy.  Therefore, it is essential to develop the US-responsive and cell-selective gene 
carriers constructed with ligand-modified gene carriers and microbubbles. 
Taking these into considerations, we examined the gene transfection system for 
effective DNA vaccine therapy using physical stimulation and ligand-modification.  First, 
we developed US-responsive and mannose-modified gene carriers, Man-PEG2000 bubble 
lipoplexes (Fig. 1), by enclosing perfluoropropane gas into mannose-conjugated 



































































1))/pDNA complexes.  Then, we evaluated the enhanced and cell-selective gene expression 
in the APCs by intravenous administration of Man-PEG2000 bubble lipoplexes and external US 
exposure in mice.  Finally, we examined high anti-tumor effects by applying this method to 



































































2. Materials and Methods 
2.1. Mice and cell lines 
Female ICR mice (4-5 weeks old) and C57BL/6 mice (6-8 weeks old) were purchased 
from the Shizuoka Agricultural Cooperative Association for Laboratory Animals (Shizuoka, 
Japan).  All animal experiments were carried out in accordance with the Principles of 
Laboratory Animal Care as adopted and promulgated by the US National Institutes of Health 
and the guideline for animal experiments of Kyoto University.  CD8-OVA1.3 cells, T-cell 
hybridomas with specificity for OVA (257-264)-kb, were kindly provided by Dr. C.V. 
Harding (Case Western Reserve University, Cleveland, OH, USA) [18].  EL4 cells 
(C57BL/6 T lymphomas) and E.G7-OVA cells (the OVA-transfected clones of EL4) were 
purchased from American Type Culture Collection (Manassas, VA).  CD8-OVA1.3 cells 
and EL4 cells were maintained in Dulbecco‟s modified Eagle‟s medium and E.G7-OVA cells 
were maintained in RPMI 1640.  Both mediums were supplemented with 10% fetal bovine 
serum (FBS), 0.05 mM 2-mercaptoethanol, 100 IU/mL penicillin, 100 g/mL streptomycin 
and 2 mM L-glutamine at 37 °C in 5% CO2. 
 
2.2. pDNA 
pCMV-Luc and pCMV-OVA were constructed in our previous reports [19,20].  
Briefly, pCMV-Luc was constructed by subcloning the HindIII/Xba I firefly luciferase cDNA 
fragment from pGL3-control vector (Promega, Madison, WI, USA) into the polylinker of 
pcDNA3 vector (Invitrogen, Carlsbad, CA, USA).  pCMV-OVA was constructed by 
subcloning the EcoRI chicken egg albumin (ovalbumin) cDNA fragment from pAc-neo-OVA, 
which was kindly provided by Dr. M.J. Bevan (University of Washington, Seattle, WA, USA) 



































































and purified using a QIAGEN Endofree Plasmid Giga Kit (QIAGEN GmbH, Hilden, 
Germany). 
 
2.3. Synthesis of Man-PEG2000-DSPE and preparation of Man-PEG2000 bubble lipoplexes 
Man-PEG2000-DSPE was synthesized in a one-step reaction by covalent binding with 
NH2-PEG2000-DSPE (NOF Co., Tokyo, Japan) and 2-imino-2-methoxyethyl-1-thiomannoside 
(IME-thiomannoside).  IME-thiomannoside was prepared according to the method of Lee et 
al. [21].  Next, NH2-PEG2000-DSPE and IME-thiomannoside were reacted, vacuum dried and 
dialyzed to produce Man-PEG2000-DSPE, and then, the resultant dialysates were lyophilized.  
To produce the liposomes for bubble lipoplexes, DSTAP (Avanti Polar Lipids Inc., Alabaster, 
AL, USA), DSPC (Sigma Chemicals Inc., St. Louis, MO, USA) and Man-PEG2000-DSPE or 
NH2-PEG2000-DSPE were mixed in chloroform at a molar ratio of 7:2:1.  For construction of 
BLs, DSPC and methoxy-PEG2000-DSPE (NOF Co., Tokyo, Japan) were mixed in chloroform 
at a molar ratio of 94:6.  The mixture for the construction of liposomes was dried by 
evaporation, vacuum desiccated and the resultant lipid film was resuspended in sterile 5% 
dextrose.  After hydration for 30 min at 65 °C, the dispersion was sonicated for 10 min in a 
bath sonicator and for 3 min in a tip sonicator to produce liposomes.  Then, liposomes were 
sterilized by passage through a 0.45 μm filter (Nihon-Millipore, Tokyo, Japan).  The 
lipoplexes were prepared by gently mixing with equal volumes of pDNA and liposome 
solution at a charge ratio of 1.0:2.3 (-:+).  For preparation of BLs and bubble lipoplexes, the 
enclosure of US imaging gas into liposomes and lipoplexes was performed according to our 
previous report [16].  Briefly, prepared liposomes and lipoplexes were added to 5 mL 
sterilized vials, filled with perfluoropropane gas (Takachiho Chemical Industries Co., Ltd., 



































































US imaging gas into the liposomes and lipoplexes, the vial was sonicated using a bath-type 
sonicator (AS ONE Co., Osaka, Japan) for 5 min.  The particle sizes and zeta potentials of 
liposomes and lipoplexes were determined by a Zetasizer Nano ZS instrument (Malvern 
Instrument, Ltd., Worcestershire, UK). 
 
2.4. Harvesting of mouse peritoneal macrophages 
Mouse peritoneal macrophages were harvested and cultured according to our previous 
report [16].  Briefly, the macrophages were harvested from mice at 4 days after 
intraperitoneal injection of 2.9% thioglycolate medium (1 mL).  The collected macrophages 
were washed and suspended in RPMI-1640 medium supplemented with 10% FBS, 100 
IU/mL penicillin, 100 g/mL streptomycin and 2 mM L-glutamine, and plated on culture 
plates.  After incubation for 2 hr at 37 °C in 5% CO2, non-adherent cells were washed off 
with culture medium, and the macrophages were incubated for another 72 hr. 
 
2.5. In-vitro gene transfection 
After the macrophages were collected and incubated for 72 hr, the culture medium was 
replaced with Opti-MEM I containing bubble lipoplexes (5 μg pDNA).  The macrophages 
were exposed to US (frequency, 2.062 MHz; duty, 50%; burst rate, 10 Hz; intensity 4.0 
W/cm
2
) for 20 seconds using a 6 mm diameter probe placed in the well at 5 min after addition 
of bubble lipoplexes.  In the transfection using naked pDNA and BLs, at 5 min after addition 
of naked pDNA (5 μg) and BLs (60 μg total lipids) were added, and the macrophages were 
immediately exposed to US.  US was generated using a Sonopore-4000 sonicator (NEPA 
GENE, Chiba, Japan).  Then, 1 hr later, the incubation medium was replaced with 
RPMI-1640 and incubated for an additional 23 hr.  Lipofectamine
®



































































Carlsbad, CA, USA) was used according to the recommended procedures, and the exposure 
time of Lipofectamine
®
 2000 was 1 hr, which is the same exposure time in other experiments 
using lipoplexes.  Following incubation for 24 hr, the cells were scraped from the plates and 
suspended in lysis buffer (0.05% Triton X-100, 2 mM EDTA, 0.1 M Tris, pH 7.8).  Then, 
the cell suspension was shaken, and centrifuged at 10,000 × g, 4 °C for 10 min.  The 
supernatant was mixed with luciferase assay buffer (Picagene, Toyo Ink Co., Ltd., Tokyo, 
Japan) and the luciferase activity was measured in a luminometer (Lumat LB 9507, EG&G 
Berthold, Bad Wildbad, Germany).  The luciferase activity was normalized with respect to 
the protein content of cells.  The protein concentration was determined with a Protein 
Quantification Kit (Dojindo Molecular Technologies, Inc., Tokyo, Japan).  The level of 
luciferase mRNA expression was determined by RT-PCR. 
 
2.6. Inhibitory experiments of endocytosis in-vitro 
Endocytosis was inhibited by chlorpromazine (50 μM) as clathrin-mediated endocytosis 
inhibitor [22], genistein (200 μM) as caveolae-mediated endocytosis inhibitor [23] and 
5-(N-ethyl-N-isopropyl)amiloride (EIPA, 50 μM) as macropinocytosis inhibitor [24].  Each 
endocytosis inhibitor was added to the macrophages at 30 min before the addition of 
lipoplexes. 
 
2.7. Fluorescence photographs of pDNA in mouse peritoneal macrophages 
To visualize the cellular association of pDNA by fluorescence microscopy (Biozero 
BZ-8000, KEYENCE, Osaka, Japan), lipoplexes were constructed with 
TM-rhodamine-labeled pDNA prepared by a Label IT Nucleic Acid Labeling Kit (Mirus Co., 




































































2.8. Evaluation of cytotoxic effects by MTT assay 
The cytotoxicity was evaluated by MTT assay.  Briefly, 
3-(4,5-dimethyl-2-thiazol)-2,5-diphenyltetrazolium bromide (MTT, Nacalai Tesque, Inc., 
Kyoto, Japan) solution was added to each well and incubated for 4 hr.  The resultant 
formazan crystals were dissolved in 0.04 M HCl-isopropanol and sonicated for 10 min in a 
bath sonicator.  Absorbance values at 550 nm (test wavelength) and 655 nm (reference 
wavelength) were measured and the results were expressed as viability (%). 
 
2.9. In-vivo gene transfection 
Four-week-old ICR female mice were intravenously injected with 400 μL bubble 
lipoplexes via the tail vein using a 26-gauge syringe needle at a dose of 50 μg pDNA.  At 5 
min after the injection of bubble lipoplexes, US (frequency, 1.045 MHz; duty, 50%; burst rate, 
10 Hz; intensity 1.0 W/cm
2
; time, 2 min) was exposed transdermally to the abdominal area 
using a Sonopore-4000 sonicator with a probe of diameter 20 mm.  In the transfection using 
naked pDNA and BLs, at 4 min after intravenous injection of BLs (500 g total lipid), naked 
pDNA (50 g) was intravenously injected and US was exposed at 1 min after naked pDNA 
injection.  At predetermined times after injection, mice were sacrificed and their organs 
collected for each experiment.  The organs were washed twice with cold saline and 
homogenized with lysis buffer (0.05% Triton X-100, 2 mM EDTA, 0.1 M Tris, pH 7.8).  
The lysis buffer was added in a weight ratio of 5 mL/g for the liver or 4 mL/g for the other 
organs.  After three cycles of freezing and thawing, the homogenates were centrifuged at 
10,000 × g, 4 °C for 10 min.  The luciferase activity of resultant supernatant was determined 




































































2.10. In-vivo imaging 
At 6 hr after transfection, anesthetized mice were administrated D-luciferin (10 mg/300 
μL PBS) (Promega Co., Madison, WI, USA).  At 10 min after injection of D-luciferin, 
organs were excised and luminescent images were taken by NightOWL LB 981 NC 
instrument (Berthold Technologies, GmbH, Bad Wildbad, Germany).  The pseudocolor 
luminescent images were generated, overlaid with organ images and the luminescence 
representation was obtained using WinLight software (Berthold Technologies GmbH, Bad 
Wildbad, Germany). 
 
2.11. Separation of mouse hepatic PCs and NPCs 
The separation of mouse hepatic PCs and NPCs was performed according to our 
previous reports [19].  Briefly, at 6 hr after in-vivo transfection using bubble lipoplexes and 
US exposure, each mouse was anesthetized with pentobarbital sodium (40-60 mg/kg) and the 




-free HEPES solution, pH 7.2) for 10 min.  
Then, the liver was perfused with collagenase buffer (HEPES solution, pH 7.5 containing 5 
mM CaCl2 and 0.05 % (w/v) collagenase (type I)) for 5 min.  Immediately after the start of 
perfusion, the vena cava and aorta were cut and the perfusion rate was maintained at 5 
mL/min.  At the end of perfusion, the liver was excised.  The cells were dispersed in 
ice-cold Hank‟s-HEPES buffer by gentle stirring and then filtered through cotton mesh sieves, 
followed by centrifugation at 50 × g for 1 min.  The pellets containing the hepatic PCs were 
washed five times with Hank‟s-HEPES buffer by centrifuging at 50 × g for 1 min.  The 
supernatant containing the hepatic NPCs was similarly centrifuged 5 times and the resulting 



































































resuspended separately in ice-cold Hank‟s-HEPES buffer. 
 
2.12. Isolation of mouse splenic CD11c
+
 cells 
The isolation of mouse splenic CD11c
+
 cells was performed according to our previous 
reports [25].  Briefly, At 6 hr after in-vivo transfection using bubble lipoplexes and US 
exposure, the splenic cells were suspended in ice-cold RPMI-1640 medium on ice.  Red 
blood cells were removed by incubation with hemolytic reagent (0.15 M NH4Cl, 10 mM 
KHCO3, 0.1 mM EDTA) for 3 min at room temperature.  The CD11c
+
 cells were isolated by 
magnetic cell sorting with anti-mouse CD11c (N418) microbeads and auto MACS (Miltenyi 
Biotec, Inc., Auburn, CA, USA) following the manufacturer‟s instructions. 
 
2.13. Quantitative RT-PCR 
     Total RNA was isolated from separated cells using a GenElute Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich, St. Louis, MO, USA).  Reverse transcription of mRNA was 
carried out using a PrimeScript
®
 RT reagent Kit (Takara Bio Inc., Shiga, Japan).  Real-time 
PCR was performed using SYBR
®
 Premix Ex Taq (Takara Bio Inc., Shiga, Japan) and 
Lightcycler Quick System 350S (Roche Diagnostics, Indianapolis, IN, USA) with primers.  
The primers for luciferase and gapdh cDNA were constructed as follows: primer for luciferase 
cDNA, 5‟-TTCTTCGCCAAAAGCACTC-3‟ (forward) and 
5‟-CCCTCGGGTGTAATCAGAAT-3‟ (reverse); primer for gapdh, 
5‟-TCTCCTGCGACTTCAACA-3‟ (forward) and 5‟-GCTGTAGCCGTATTCATTGT-3‟ 
(reverse) (Sigma-aldrich, St. Louis, MO, USA).  The mRNA copy numbers were calculated 
for each sample from the standard curve using the instrument software („Arithmetic Fit Point 



































































copy numbers to the housekeeping gene (gapdh) mRNA copy numbers. 
 
2.14. Tissue distribution of radio-labeled pDNA 
Lipoplexes constructed with 
32
P-labeled pDNA ([-32P]-dCTP, PerkinElmer, Inc., MA, 
USA) [26] were injected intravenously into mice.  At predetermined times after injection, 
blood was collected from the vena cava under pentobarbital anesthesia.  Then, mice were 
sacrificed and the organs were collected, rinsed with saline and weighed.  The tissues were 
dissolved in Soluene-350 and the resultant lysates were decolorized with isopropanol and 
30% H2O2, and then neutralized with 5 N HCl.  The radioactivity of 
32
P-labeled pDNA was 
measured in scintillation counter (LSA-500, Beckman Coulter, Inc., CA, USA) after addition 
of Clear-Sol I solution. 
 
2.15. Measurement of transaminase activity in the serum 
At predetermined times after transfection, the serum was collected from the 
anesthetized mice.  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
activities in the serum were determined using Transaminase CII-Test Wako kit (Wako Pure 
Chemical Industries Ltd., Tokyo, Japan) according to manufacturer‟s instructions. 
 
2.16. Antigen presenting assay 
The evaluation of antigen presentation on MHC class I molecules in the splenic 
dendritic cells was performed by in-vitro antigen presentation assay using CD8-OVA1.3 cells, 
which are T-cell hybridomas with specificity for OVA.  The CD11c
+
 cells isolated from 
immunized mice were plated in a 96-well plate at various cells numbers and co-cultured with 
CD8-OVA1.3 cells (1 × 10
5



































































was evaluated by IL-2 secreted from activated CD8-OVA1.3 cells measured by a commercial 
IL-2 ELISA Kit (Bay bioscience Co., Ltd., Hyogo, Japan). 
 
2.17. Evaluation of OVA-specific cytokine secretion from the splenic cells 
At 2 weeks after the last immunization, the splenic cells collected from immunized 
mice were plated in 96-well plates and incubated for predetermined times at 37 °C in the 
presence or absence of OVA (100 μg).  IFN- and IL-4 in the culture medium were 
measured by the commercial ELISA Kit, respectively (Bay bioscience Co., Ltd., Hyogo, 
Japan). 
 
2.18. OVA-specific CTL assay 
At 2 weeks after the last immunization, the splenic cells harvested from immunized 
mice were plated in 6-well plates and co-incubated with mitomycin C-treated E.G7-OVA 
cells or EL4 cells for 4 days.  After co-incubation, non-adherent cells were collected, washed 
and plated in 96-well plates with target cells (E.G7-OVA cells or EL4 cells) at various 
effector/target (E/T) ratios.  The target cells were labeled with 
51
Cr by incubating with 
Na2
51
CrO4 (PerkinElmer, Inc., MA, USA) in culture medium for 1 hr at 37 °C.  At 4 hr after 
incubation, the plates were centrifuged and the resultant supernatant of each well was 
collected and the radioactivity of released 
51
Cr was measured in a gamma counter.  The 
percentage of 
51
Cr release was calculated as follows: specific lysis (%) = [(experimental 
51
Cr 




Cr release - spontaneous 
51
Cr release)] × 100).  
The percentage of OVA-specific 
51
Cr release was calculated as (% of 
51
Cr release from 
E.G7-OVA cells) - (% of 
51




































































2.19. Therapeutic effects 
C57BL/6 mice were immunized three times bi-weekly.  At 2 weeks after last 
immunization, E.G7-OVA cells and EL4 cells were transplanted subcutaneously into the back 
of mice.  The tumor growth and survival of mice were monitored up to 80 days after 
transplantation of E.G7-OVA cells and EL4 cells. 
 
2.20. Statistics 
Results were presented as the mean ± SD of more than three experiments.  Analysis of 
variance (ANOVA) was used to test the statistical significance of differences among groups.  
Two-group comparisons were performed by the Student‟s t-test.  Multiple comparisons 
between control groups and other groups were performed by the Dunnett‟s test and multiple 




































































3.1. In-vitro gene transfection properties by Man-PEG2000 lipoplexes 
Polyethylene-glycol (PEG) modification of particles is necessary to enclose US 
imaging gas stably and to prepare the small-sized microbubbles for in-vivo administration 
[12].  Firstly, we developed mannose-conjugated PEG2000-modified lipids 
(Man-PEG2000-DSPE (Fig. 1)) to prepare the APC-targeted small sized microbubbles and 
determined the in-vitro and in-vivo transfection characteristics of mannose-conjugated 
PEG2000-modified lipoplexes (Man-PEG2000 lipoplexes) containing Man-PEG2000 lipids.  The 
particle sizes and zeta potentials of Man-PEG2000 lipoplexes and non-modified 
PEG2000-lipoplexes (Bare-PEG2000 lipoplexes) were approximately 150 nm and +40 mV, 
respectively (Supplementary Table 1).  In mouse cultured macrophages expressing mannose 
receptors abundantly, the level of gene expression obtained by Man-PEG2000 lipoplexes were 
significantly higher than those by Bare-PEG2000 lipoplexes (Figs. 2A and 2B).  Then, the 
level of gene expression obtained by Man-PEG2000 lipoplexes was suppressed to same extent 
as that by Bare-PEG2000 lipoplexes in the presence of an excess of mannan (Fig. 2A).  
Moreover, this level of gene expression obtained by Man-PEG2000 lipoplexes was also 
suppressed to same extent as that by Bare-PEG2000 lipoplexes in the presence of 
chlorpromazine (Fig. 2B), which is the inhibitor of clathrin-mediated endocytosis [22].  
These results agreed with the results of cellular association of pDNA (Supplementary Fig. 1), 
and suggest that Man-PEG2000 lipoplexes are taken up into the cells via clathrin-mediated 
endocytosis following the interaction with mannose receptors. 
 
3.2. In-vivo gene transfection properties by Man-PEG2000 lipoplexes 



































































the in-vivo gene transfection by intravenously administration of lipoplexes, we investigated 
the stability of Bare-PEG2000 lipoplexes and Man-PEG2000 lipoplexes against nucleases.  
Following electrophoresis of naked pDNA and lipoplexes after incubation with DNase I, 
although naked pDNA underwent the degradation by DNase I, lipoplexes did not undergo the 
degradation and retained the complex forms (Supplementary Fig. 2).  Then, we investigated 
the gene expression characteristics of Man-PEG2000 lipoplexes in the liver and spleen, which 
are the targeted organs of mannose-modified carriers [27].  In this study, liver was separated 
in the parenchymal cells (PCs) and non-parenchymal cells (NPCs), and spleen was separated 
in the dendritic cells (CD11c
+
 cells) and other cells (CD11c
-
 cells).  As shown in Figs. 2C 
and 2D, following intravenous administration of Man-PEG2000 lipoplexes, selective gene 
expression was observed in the hepatic NPCs and the splenic CD11c
+
 cells, which are the 
APCs expressing mannose receptors abundantly [28-30]. 
 
3.3. In-vitro gene transfection efficiency by Man-PEG2000 bubble lipoplexes and US exposure 
Although Man-lipoplexes showed the APC-selective gene transfection properties in 
vivo, this level of gene expression was low compared with our previous reports [1,19,25].  
To enhance the level of gene expression by sonoporation method, we developed Man-PEG2000 
bubble lipoplexes (Fig. 1) by enclosing US imaging gas (perfluoropropane gas) into 
Man-PEG2000 lipoplexes.  The lipid composition of lipoplexes is important for the stable 
enclosure of US imaging gas.  Following optimization of lipid composition, lipoplexes 
constructed with the saturated lipids only, which have a high melting temperature (Tm), were 
enclosed US imaging gas stably (Supplementary Table 2).  Following enclosure of US 
imaging gas in lipoplexes, lipoplexes became cloudy and their particle sizes were increased 



































































3).  Then, since the zeta potentials of bubble lipoplexes were lower than that of bubble 
liposomes and same as that of lipoplexes (Supplementary Tables 1 and 3), it is considered that 
pDNA is attached on the surface of bubble liposomes.  Moreover, the stability against 
nucleases observed in Man-PEG2000 lipoplexes (Supplementary Fig. 2) was maintained after 
enclosure of US imaging gas into lipoplexes (Supplementary Fig. 3B). 
The level of gene expression obtained by Man-PEG2000 bubble lipoplexes and US 
exposure was 500-fold higher than that by Man-PEG2000 lipoplexes in mouse cultured 
macrophages expressing mannose receptors abundantly, and also higher than that by 
non-modified bubble lipoplexes (Bare-PEG2000 bubble lipoplexes, Fig. 1) and US exposure or 
conventional sonoporation method using naked pDNA and BLs (Fig. 3A).  This enhanced 
gene expression was observed when bubble lipoplexes and US exposure were used for 
in-vitro gene transfer (Fig. 3B).  The cellular association of pDNA obtained by transfection 
using Man-PEG2000 bubble lipoplexes and US exposure was also 10-fold higher than that by 
Man-PEG2000 lipoplexes, and also higher than that by Bare-PEG2000 bubble lipoplexes and US 
exposure or conventional sonoporation method using naked pDNA and BLs (Fig. 3C and 
Supplementary Fig. 4A).  Moreover, this level of gene expression obtained by Man-PEG2000 
bubble lipoplexes and US exposure was comparable to that by Lipofectamine
®
 2000, which is 
widely used as a gene transfection reagent (Fig. 3D).  On the other hand, the cytotoxicity by 
Man-PEG2000 bubble lipoplexes and US exposure was lower than that by Lipofectamine
®
 
2000 (Fig. 3E). 
 
3.4. Intracellular uptake properties of pDNA by Man-PEG2000 bubble lipoplexes and US 
exposure 



































































significantly suppressed in the presence of an excess of mannan (Fig. 4A).  Therefore, the 
interaction with mannose receptors on the cell membrane is involved in the gene transfection 
by Man-PEG2000 bubble lipoplexes and US exposure, similar to the gene transfection by 
Man-PEG2000 lipoplexes.  On the other hand, unlike Man-PEG2000 lipoplexes (Fig. 2B), the 
gene expression obtained by Man-PEG2000 bubble lipoplexes and US exposure was not 
suppressed in the presence of chlorpromazine (Fig. 4B), which is a clathrin-mediated 
endocytosis inhibitor [22].  These results agreed with the results of cellular association of 
pDNA (Supplementary Fig. 4B), and indicated that pDNA delivered by Man-PEG2000 bubble 
lipoplexes was directly introduced into the cytoplasm without mediating endocytosis by the 
gene transfection using Man-PEG2000 bubble lipoplexes and US exposure. 
 
3.5. In-vivo gene transfection efficiency by Man-PEG2000 bubble lipoplexes and US exposure 
As shown in Figs. 5A and 5B, the level of gene expression obtained by Man-PEG2000 
bubble lipoplexes and US exposure was 500~800-fold higher than that by Man-PEG2000 
lipoplexes, and also higher than that by Bare-PEG2000 bubble lipoplexes and US exposure or 
the conventional sonoporation method using naked pDNA and BLs in the liver and spleen, 
which are the targeted organs of mannose-modified carriers [27].  This enhanced gene 
expression in the liver and spleen was observed when bubble lipoplexes and US exposure 
were used for in-vivo gene transfer (Figs. 5C and 5D).  Moreover, this gene expression 
obtained by Bare-PEG2000 bubble lipoplexes with US exposure or Man-PEG2000 bubble 
lipoplexes with US exposure in the liver and spleen remained higher than that by 
Bare-PEG2000 lipoplexes or Man-PEG2000 lipoplexes for at least 48 hr, respectively (Figs. 5E 
and 5F).  In addition, the gene expression was also enhanced in the US-exposed organ 



































































intravenous administration of Man-PEG2000 bubble lipoplexes (Supplementary Fig. 5).  On 
the other hand, the increase of gene expression by bubble lipoplexes and US exposure was not 
observed in other organ such as lung, kidney and heart (Figs. 5G and 5H). 
 
3.6. Targeted cell-selective gene transfection properties by Man-PEG2000 bubble lipoplexes 
and US exposure in vivo 
We investigated the mannose receptor-expressing cell selectivity of gene expression by 
transfection using Man-PEG2000 bubble lipoplexes and US exposure.  In the liver, the level of 
gene expression in the hepatic NPCs expressing mannose receptors was significantly higher 
than that in the hepatic PCs following gene transfection by Man-PEG2000 bubble lipoplexes 
and US exposure (Fig. 6A).  This difference in gene expression between the NPCs and PCs 
obtained by Man-PEG2000 bubble lipoplexes and US exposure was similar to that by 
Man-PEG2000 lipoplexes, although the level of gene expression in the NPCs and PCs was 
markedly higher.  On the other hand, selective gene expression in the NPCs was not 
observed by Bare-PEG2000 bubble lipoplexes and US exposure. 
In the spleen, the level of mRNA expression in the CD11c
+
 cells, which are the splenic 
dendritic cells expressing mannose receptors, was significantly higher than that in the CD11c
-
 
cells following transfection by Man-PEG2000 bubble lipoplexes and US exposure (Fig. 6B).  
On the other hand, selective gene expression in the CD11c
+
 cells was not observed by 
Bare-PEG2000 bubble lipoplexes and US exposure. 
 
3.7. In-vivo distribution properties of pDNA by Man-PEG2000 bubble lipoplexes and US 
exposure 



































































Man-PEG2000 bubble lipoplexes and US exposure, we investigated the effect on the tissue 
distribution of pDNA followed by gene transfection.  In this study, Bare-PEG2000 bubble 
lipoplexes and Man-PEG2000 bubble lipoplexes constructed with radio-labeled pDNA were 
intravenously administrated, and then mice were subjected to external US exposure.  As 
shown in Fig. 7, in the case of both bubble lipoplexes, the retention time of pDNA in the 
blood was slightly reduced and the distribution of pDNA delivered by bubble lipoplexes was 
significantly increased by US exposure in the liver and spleen (Fig. 7).  Moreover, the 
amount of pDNA distributed in the liver and spleen by Man-PEG2000 bubble lipoplexes and 
US exposure (Fig. 7A) was higher than that by Bare-PEG2000 bubble lipoplexes and US 
exposure (Fig. 7B).  On the other hand, no increase of pDNA distribution followed by US 
exposure was observed in the lung. 
 
3.8. The liver toxicity by Man-PEG2000 bubble lipoplexes and US exposure 
We examined ALT and AST activities in the serum to investigate the liver toxicity by 
gene transfection using Man-PEG2000 bubble lipoplexes and US exposure.  ALT and AST 
activities in the serum were increased by gene transfection using Bare-PEG2000 lipoplexes and 
Man-PEG2000 lipoplexes.  On the other hands, the increase of ALT and AST activities was 
not observed by gene transfection using Bare-PEG2000 bubble lipoplexes and Man-PEG2000 
bubble lipoplexes with US exposure (Fig. 8). 
 
3.9. Antigen presentation on MHC class I molecules in immunized splenic dendritic cells 
To investigate the DNA vaccine effects by Man-PEG2000 bubble lipoplexes and US 
exposure, we prepared Man-PEG2000 bubble lipoplexes constructed with pDNA expressing 



































































class I molecules in the splenic dendritic cells (CD11c
+
 cells) by Man-PEG2000 bubble 
lipoplexes constructed with pCMV-OVA and US exposure, the splenic CD11c
+
 cells isolated 
from once-immunized mice were co-incubated with CD8-OVA1.3 cells, which are T-cell 
hybridomas with specificity for OVA.  Following measurement of IL-2 to evaluate the 
activation of T-cells, the IL-2 secretion from activated CD8-OVA1.3 cells co-incubated with 
the CD11c
+
 cells isolated from mice immunized by Man-PEG2000 bubble lipoplexes and US 
exposure was the highest of all (Fig. 9A).  This result indicates that DNA vaccination by 
Man-PEG2000 bubble lipoplexes constructed with pCMV-OVA and US exposure can induce 
significantly high CD8
+
-T lymphocyte activation. 
 
3.10. Antigen-specific cytokine secretion from immunized splenic cells 
We evaluated the OVA-specific cytokine secretion from the splenic cells immunized by 
Man-PEG2000 bubble lipoplexes constructed with pCMV-OVA and US exposure.  Following 
optimization of immunization schedule, it was shown that a 2-week interval was necessary to 
achieve the same level of gene expression as former transfection in the spleen (Supplementary 
Fig. 6) and at least three-times immunization was necessary to effective anti-tumor effects by 
DNA vaccination using this method (Supplementary Fig. 7).  Therefore, the immunization to 
mice was performed according to the protocol shown in Fig. 9B.  As shown in Fig. 9C, in 
the presence of OVA, the highest amount of IFN- (Th1 cytokine) was secreted from splenic 
cells harvested from mice immunized with Man-PEG2000 bubble lipoplexes and US exposure.  
On the other hand, no secretion of IFN- was observed in any of the groups in the absence of 
OVA.  Moreover, the secretion of IL-4 (Th2 cytokine) was not increased in any of the groups 
both in the presence or absence of OVA (Fig. 9C).  These results suggest that immunization 



































































significantly enhances the differentiation of helper T cells to Th1 cells, which are pivotal cells 
for the activation of cytotoxic T lymphocytes (CTL) with high anti-tumor activity, by 
OVA-stimulation. 
 
3.11. Antigen-expressing cell specific CTL activity in immunized splenic cells 
Next, we assessed the CTL activity in the splenic cells harvested from mice immunized 
by Man-PEG2000 bubble lipoplexes and US exposure.  Following experiments according to 
the protocol shown in Fig. 9B, the splenic cells immunized by Man-PEG2000 bubble 
lipoplexes constructed with pCMV-OVA and US exposure showed the highest CTL activity in 
all groups against E.G7-OVA cells which are the lymphoma cells expressing OVA (Fig. 9D).  
In contrast, the CTL activity was not observed in EL4 cells which are the lymphoma cells not 
expressing OVA in all groups (Fig. 9D).  These results indicate that the splenic cells 
immunized by Man-PEG2000 bubble lipoplexes constructed with pCMV-OVA and US 
exposure induce the OVA-expressing cell specific CTL activity. 
 
3.12. Therapeutic effects against antigen-expressing tumor by DNA vaccination 
Finally, we investigated the anti-tumor effects by DNA vaccination using Man-PEG2000 
bubble lipoplexes and US exposure.  Following experiments according to the protocol 
shown in Fig. 10A, significantly high anti-tumor effects against E.G7-OVA cells were 
observed in mice immunized by Man-PEG2000 bubble lipoplexes constructed with 
pCMV-OVA and US exposure (Fig. 10B).  However, in mice transplanted EL4 cells, no 
anti-tumor effects were observed in any of the groups (Fig. 10C).  Moreover, we investigated 
the maintenance of DNA vaccine effects following administration of Man-PEG2000 bubble 



































































were re-transplanted into mice which first-transplanted tumors were completely rejected by 
DNA vaccination using Man-PEG2000 bubble lipoplexes and US exposure.  As results, high 
anti-tumor effects were observed in mice following re-transplantation of E.G7-OVA cells (Fig. 
11B); therefore it was demonstrated that DNA vaccine effects obtained by Man-PEG2000 





































































To obtain high therapeutic effects by DNA vaccination using tumor specific 
antigen-coding gene, it is essential to transfer the gene selectively and efficiently into the 
APCs, such as macrophages and dendritic cells [31,32].  However, it is difficult to transfer 
the gene into the APCs selectively because of the number of APCs is limited in the organ [33].  
Since the APCs are expressed a large number of mannose receptors [28,29], we and other 
groups have developed mannose-modified non-viral carriers for gene delivery to the APCs 
[7,25,34].  On the other hand, our group also reported that the gene transfection efficiency in 
the APCs was lower than that in other cells [35]; therefore it is difficult to achieve high gene 
transfection efficiency to induce high therapeutic effects by DNA vaccination in vivo.  In the 
present study, to establish an APC-selective and efficient gene delivery system, we developed 
US-responsive and mannose-modified carriers, named Man-PEG2000 bubble lipoplexes, which 
had selectivity to the APCs and responded to US exposure.  The gene delivery system using 
Man-PEG2000 bubble lipoplexes and US exposure enabled to achieve markedly high gene 
expression in macrophages and dendritic cells selectively in vivo, in spite of the handy system 
used intravenous administration and external US exposure.  Moreover, we succeeded in 
obtaining high anti-tumor effects by applying this method to DNA vaccine therapy using 
OVA-expressing pDNA. 
Firstly, since PEG2000-modification is necessary to enclose US imaging gas stably [12], 
we prepared Man-PEG2000 lipoplexes containing Man-PEG2000 lipids.  This Man-PEG2000 
lipoplexes exhibited mannose receptor-expressing cell-selective gene expression both in vitro 
and vivo (Fig. 2).  On the other hand, the level of gene expression by Man-PEG2000 
lipoplexes was lower than that by mannosylated lipoplexes without PEG-modification, as 



































































contributed by the reduced interaction with the cell membrane and the reduction of endosomal 
escape efficiency by PEG2000-modification [36,37].  In the sonoporation method, Tachibana 
et al. demonstrated that a transient pore is created on the cell membrane followed by the 
degradation of microbubbles [38].  Then, nucleic acids, such as pDNA, siRNA and 
oligonucleotides, are introduced into the cell through the generated pore [13,15,16].  
Consequently, since the nucleic acids are directly introduced into cytoplasm in the 
sonoporation method [13,14], it is considered that the low level of transfection efficiency 
obtained by Man-PEG2000 lipoplexes can be overcome by applying sonoporation method.  
As shown in Figs. 3 and 4, a large amount of pDNA is directly introduced into the cytoplasm 
and high level of gene expression is observed by gene transfection using Man-PEG2000 bubble 
lipoplexes and US exposure.  Therefore, by delivering pDNA to the APCs using 
Man-PEG2000 bubble lipoplexes, it is suggested that high level of gene expression in the APCs 
can easily achieve by following US exposure in this gene transfection method. 
In this study, the level of gene expression obtained by transfection using Man-PEG2000 
bubble lipoplexes and US exposure was higher than that obtained by Man-PEG2000 lipoplexes 
or Bare-PEG2000 bubble lipoplexes with US exposure in the liver and spleen (Fig. 5).  
Moreover, gene expression by Man-PEG2000 bubble lipoplexes and US exposure was observed 
selectively in the hepatic NPCs and the splenic dendritic cells (Fig. 6), known as mannose 
receptor-expressing cells [28-30].  Although this selectivity of gene expression was the same 
as that obtained by mannosylated lipoplexes reported previously by our group [1,25], this 
level of gene expression was markedly higher.  It is considered that this enhanced and 
cell-selective gene expression is contributed by the increase of interaction with mannose 
receptor-expressing cells by mannose modification (Supplementary Fig. 1), by the 



































































the direct introduction of nucleic acids into the cytoplasm of targeted cells followed by US 
exposure to Man-PEG2000 bubble lipoplexes (Figs. 3C, 4B and Supplementary Fig. 4).  
Moreover, the enhanced gene expression was not observed in the lung, kidney and spleen 
(Figs. 5G and 5H).  It is guessed that the reason why the enhanced gene expression was not 
observed in the lung is because US is not spread to the thoracic cavity by the diaphragm, and 
the reason why the enhanced gene expression was not observed in the kidney and heart was 
because the distributed amounts of bubble lipoplexes were markedly small.  In addition, 
since the particle size of bubble lipoplexes (approximately 500 nm) is suitable for delivery to 
the liver and spleen, compared with stabilized liposomes (approximately 100 nm) [39], the 
gene transfection system using Man-PEG2000 bubble lipoplexes and US exposure is a suitable 
method for the selective delivery of nucleic acids into the mannose receptor-expressing cells 
in the liver and spleen. 
On the other hand, the liver toxicity followed by gene transfection using Man-PEG2000 
bubble lipoplexes and US exposure was lower than that by Man-PEG2000 lipoplexes (Fig. 8).  
It was reported that the CpG motifs in the pDNA sequence are recognized to Toll-like receptor 
9 (TLR9) in the endosomes [40,41]; therefore it has been considered that the production of 
proinflammatory cytokines, such as TNF-, IFN- and IL-12, could be induced in the 
lipofection method using liposomes and emulsions, and these cytokines cause liver injury [42].  
However, in the gene transfection using Man-PEG2000 bubble lipoplexes and US exposure, a 
large amount of pDNA was directly introduced into the cytoplasm not-mediated endocytosis 
(Figs. 3C, 4B and Supplementary Fig. 4).  Therefore, it is considered that pDNA is not 
recognized to TLR9 in the endosomes, and consequently liver toxicity followed by 
transfection using Man-PEG2000 bubble lipoplexes and US exposure is low. 



































































lipoplexes [1] and BLs [12] with US exposure to achieve targeted cell-selective gene transfer.  
However, this combination-use method is complicated because of the necessity of twice 
injection of mannosylated lipoplexes and BLs, therefore it is difficult to apply for medical 
treatments using multiple injection.  Moreover, it is considered that the difference of in-vivo 
distribution characteristics between mannosylated lipoplexes and BLs might be decreased its 
transfection efficacy.  On the other hand, this transfection method using Man-PEG2000 bubble 
lipoplexes and US exposure is handy because of using only once injection of Man-PEG2000 
bubble lipoplexes and external US exposure.  In addition, this method using Man-PEG2000 
bubble lipoplexes and US exposure overcame the difference of in-vivo distribution of 
formulations, which might lead to the decrease of transfection efficiency.  In fact, the level 
of gene expression by this method was higher than that by combination-use method reported 
previously in the targeted organs (liver and spleen) (Fig. 5) and targeted cells (hepatic NPC 
and splenic dendritic cells) (Fig. 6); therefore this gene transfection method using 
Man-PEG2000 bubble lipoplexes and US exposure is more suitable for APC-selective gene 
transfer in vivo. 
Since APC-selective and efficient gene expression was observed by transfection using 
Man-PEG2000 bubble lipoplexes and US exposure, effective therapeutic effects are to be 
expected by applying this transfection method to DNA vaccine therapy, which the targeted 
cells are the APCs, using tumor specific antigen-coding pDNA [31,32].  However, since the 
level of gene expression by transfection using Man-PEG2000 bubble lipoplexes and US 
exposure was reduced sequentially (Supplementary Fig. 6), multiple transfections are 
essential to obtain more effective vaccine effects against cancer (Supplementary Fig. 7).  On 
the other hand, a 2-week interval was needed to achieve the same level of gene expression by 



































































(Supplementary Figs. 7B and 7C).  Meyer et al. reported that the optimal transfection 
interval was necessary to achieve high gene expression by the second transfection using 
lipofection methods because of IFN- secretion by intravenous administration of lipoplexes 
[43]; therefore it is considered that a similar phenomenon is contributed to the sonoporation 
methods using microbubbles constructed with phospholipids.  Based on these findings, we 
performed the optimization of immunization times (Supplementary Fig. 7) and determined the 
optimal immunization schedule as shown in Figs. 9B, 10A and 11A. 
In DNA vaccine therapy, unlike cancer immunotherapy using tumor-specific antigenic 
peptides, the peptides expressed as gene products in the cells act as the internal antigen.  
Since the internal antigens are presented on MHC class I molecules, the strong activation of 
CTL and high anti-tumor effects are expected in DNA vaccination therapy [44,45].  In this 
study, by applying this gene transfection method to DNA vaccine therapy using 
OVA-expressing pDNA, i) the presentation of OVA-peptides on MHC class I molecules of 
splenic dendritic cells, ii) OVA-specific Th1 cytokine secretion from splenic cells by OVA 
stimulation and iii) marked activation of CTL against OVA-expressing tumor were observed 
by gene transfection using Man-PEG2000 bubble lipoplexes constructed with pCMV-OVA and 
US exposure (Fig. 9).  Moreover, high and long-term anti-tumor effects against 
OVA-expressing tumor were observed in mice transfected by Man-PEG2000 bubble lipoplexes 
constructed with pCMV-OVA and US exposure (Figs. 10 and 11).  It is considered that these 
results are contributed by APS-selective and efficient gene transfection efficiency using 
Man-PEG2000 bubble lipoplexes and US exposure.  Although more detailed examination by 
pDNA encoding other tumor-specific antigens, such as gp100 in melanoma or PSA in prostate 
cancer [45], is necessary, this transfection method by Man-PEG2000 bubble lipoplexes and US 



































































The gene transfection method using Man-PEG2000 bubble lipoplexes and US exposure 
was enabled selective and efficient gene transfer to the mannose receptor-expressing cells in 
the liver such as Kupffer cells and hepatic endothelial cells, which are components of the 
APCs (Fig. 6A).  Therefore, this method is also suitable for anti-inflammatory therapy 
targeted to Kupffer cells and hepatic endothelial cells, known to play a key role in 
inflammation [46,47].  In spite of low liver toxicity, since this gene transfection system 
showed NPC-selective and efficient gene expression in the liver (Fig. 8), better therapeutic 
effects could be expected by Man-PEG2000 bubble lipoplexes constructed with various types 
of nucleic acids, such as NF-κB decoy [48], ICAM-1 antisense oligonucleotides [49], with 
low doses of nucleic acids.  Moreover, organ-specific gene expression was observed in 
US-exposed organ by exposing US to the organ directly after intravenous administration of 
Man-PEG2000 bubble lipoplexes (Supplementary Fig. 5); therefore the beforehand knockdown 
of inflammatory factors such as NF-κB or ICAM-1 by Man-PEG2000 bubble lipoplexes and 
US exposure might be available for the prevention of ischemia reperfusion injury, a major 




































































In this study, we developed the gene transfection method using Man-PEG2000 bubble 
lipoplexes and US exposure.  This transfection method enabled APC-selective and efficient 
gene expression, and moreover, effective anti-tumor effects was obtained by applying this 
method to DNA vaccine therapy against cancer.  This method could be widely used in a 
variety of targeted cell-selective and efficient gene transfection methods by substituting 
mannose with various ligands reported previously [2-6].  In addition, in this gene 
transfection method, pDNA can directly introduce the nucleic acids into the cells through the 
transient pores created by US-responsive degradation of bubble lipoplexes, therefore this 
method could apply to many ligands which are not taken up via endocytosis.  These findings 
make a valuable contribution to overcome the poor introducing efficiency into cytoplasm 
which is a major obstacle for gene delivery by non-viral vectors, and show that this method is 
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Fig. 1.  Structure of Bare-PEG2000 bubble lipoplex containing NH2-PEG2000-DSPE and 
Man-PEG2000 bubble lipoplex containing Man-PEG2000-DSPE used in this study. 
 
Fig. 2.  The mannose receptor-expressing cell-selective gene expression by Man-PEG2000 
lipoplexes containing Man-PEG2000 lipids in vitro and vivo.  (A) The level of luciferase 
expression obtained by Bare-PEG2000 lipoplexes and Man-PEG2000 lipoplexes (5 μg pDNA) in 
the absence or presence of 1 mg/mL mannan in mouse cultured macrophages at 24 hr after 
transfection.  ** p < 0.01, compared with the corresponding group of -mannan.  (B) 
Inhibition of luciferase expression obtained by Bare-PEG2000 lipoplexes and Man-PEG2000 
lipoplexes (5 μg pDNA) in addition of various endocytosis inhibitors in mouse cultured 
macrophages at 24 hr after transfection.  ** p < 0.01, compared with the corresponding 
group of control.  (C) The level of luciferase expression in mouse hepatic PCs and NPCs 
after intravenous administration of Bare-PEG2000 lipoplexes and Man-PEG2000 lipoplexes (50 
μg pDNA) in mice at 6 hr after transfection.  ** p < 0.01, compared with the corresponding 





 cells after intravenous administration of Bare-PEG2000 lipoplexes and 
Man-PEG2000 lipoplexes (50 μg pDNA) in mice at 6 hr after transfection.  ** p < 0.01, 
compared with the corresponding group of CD11c
-
 cells.  Each value represents the mean + 
SD (n = 3-4). 
 
Fig. 3.  Enhancement of gene expression by Man-PEG2000 bubble lipoplexes and US 
exposure in vitro.  (A) The level of luciferase expression obtained by naked pDNA, naked 
pDNA + BLs with US exposure, Bare-PEG2000 lipoplexes, Bare-PEG2000 bubble lipoplexes 
Captions
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with US exposure, Man-PEG2000 lipoplexes and Man-PEG2000 bubble lipoplexes with US 
exposure (5 μg pDNA) at 24 hr after transfection.  Significant difference; * p < 0.05; **, †† p 
< 0.01.  (B) The level of luciferase expression obtained by Man-PEG2000 lipoplexes and 
Man-PEG2000 bubble lipoplexes with or without US exposure (5 μg pDNA) at 24 hr after 
transfection.  ** p < 0.01, compared with Man-PEG2000 lipoplex, 
††
 p < 0.01, compared with 
Man-PEG2000 lipoplex + US, 
‡‡
 p < 0.01, compared with Man-PEG2000 bubble lipoplex.  (C) 
Representative fluorescent images of cellular association of pDNA obtained by Man-PEG2000 
lipoplexes and Man-PEG2000 bubble lipoplexes with US exposure (5 μg pDNA) at 2 hr after 
treatment.  Lipoplexes were constructed with TM-rhodamine-labeled pDNA.  
TM-rhodamine-labeled pDNA (red), nuclei counterstained by DAPI (blue).  Scale bars, 100 
μm.  (D) Comparison of the level of luciferase expression obtained by Man-PEG2000 bubble 
lipoplexes (5 μg pDNA) and US exposure with that by Lipofectamine 2000.  ** p < 0.01, 
compared with Man-PEG2000 lipoplexes, 
††
 p < 0.01, compared with Lipofectamine 2000 (0.1 
μg).  (E) Comparison of cell viability by transfection using Man-PEG2000 bubble lipoplexes 
(5 μg pDNA) and US exposure with that by Lipofectamine 2000.  N.T., non-treatment.  * p 
< 0.05; ** p < 0.01, compared with N.T..  Each value represents the mean + SD (n = 4). 
 
Fig. 4.  Effects of mannan and chlorpromazine on gene expression by Man-PEG2000 bubble 
lipoplexes and US exposure in vitro.  (A) The level of luciferase expression obtained by 
Bare-PEG2000 bubble lipoplexes with US exposure and Man-PEG2000 bubble lipoplexes with 
US exposure (5 μg pDNA) in the absence or presence of 1 mg/mL mannan at 24 hr after 
transfection.  ** p < 0.01, compared with the corresponding group of -mannan.  (B) The 
level of luciferase expression by Bare-PEG2000 bubble lipoplexes with US exposure and 
Man-PEG2000 bubble lipoplexes with US exposure (5 μg pDNA) in the absence or presence of 
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50 μM chlorpromazine at 24 hr after transfection.  Each value represents the mean + SD (n = 
4).  
 
Fig. 5.  Enhancement of mannose receptor-expressing cells-selective gene expression by 
Man-PEG2000 bubble lipoplexes and US exposure in vivo.  (A, B) The level of luciferase 
expression obtained by naked pDNA, naked pDNA + BLs with US exposure, Bare-PEG2000 
lipoplexes, Bare-PEG2000 bubble lipoplexes with US exposure, Man-PEG2000 lipoplexes and 
Man-PEG2000 bubble lipoplexes with US exposure (50 μg pDNA) in the liver (A) and spleen 
(B) at 6 hr after transfection.  Significant difference; **, 
††
 p < 0.01.  (C, D) The level of 
luciferase expression obtained by Man-PEG2000 lipoplexes and Man-PEG2000 bubble 
lipoplexes with or without US exposure (50 μg pDNA) in the liver (C) and spleen (D) at 6 hr 
after transfection.  ** p < 0.01, compared with Man-PEG2000 lipoplex, 
††
 p < 0.01, compared 
with Man-PEG2000 lipoplex + US, 
‡‡
 p < 0.01, compared with Man-PEG2000 bubble lipoplex.  
(E, F) Time-course of luciferase expression in the liver (E) and spleen (F) after transfection by 
Bare-PEG2000 lipoplexes, Man-PEG2000 lipoplexes, Bare-PEG2000 bubble lipoplexes with US 
exposure and Man-PEG2000 bubble lipoplexes with US exposure (50 μg pDNA).  Each value 
represents the mean ± SD (n = 4).  ** p < 0.01, compared with Bare-PEG2000 bubble lipoplex 
+ US, 
†
 p < 0.05; 
††
 p < 0.01, compared with Bare-PEG2000 lipoplex.  (G) In-vivo imaging 
photographs of luciferase expression in the isolated organs at 6 hr after transfection by 
Man-PEG2000 lipoplexes and Man-PEG2000 bubble lipoplexes with US exposure (50 μg 
pDNA).  (H) The level of luciferase expression in each organ at 6 hr after transfection by 
Bare-PEG2000 lipoplexes, Man-PEG2000 lipoplexes, Bare-PEG2000 bubble lipoplexes with US 
exposure and Man-PEG2000 bubble lipoplexes with US exposure (50 μg pDNA).  ** p < 0.01, 
compared with the corresponding group of Bare-PEG2000 lipoplex, 
††
 p < 0.01, compared with 
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the corresponding group of Man-PEG2000 lipoplex, 
‡‡
 p < 0.01, compared with the 
corresponding group of Bare-PEG2000 bubble lipoplex + US.  Each value represents the mean 
+ SD (n = 4).   
 
Fig. 6.  Hepatic and splenic cellular localization of luciferase expression by Man-PEG2000 
bubble lipoplexes and US exposure.  (A) Hepatic cellular localization of luciferase 
expression at 6 hr after transfection by Bare-PEG2000 lipoplexes, Man-PEG2000 lipoplexes, 
Bare-PEG2000 bubble lipoplexes with US exposure and Man-PEG2000 bubble lipoplexes with 
US exposure (50 μg pDNA).  ** p < 0.01, compared with the corresponding group of PCs.  
(B) Splenic cellular localization of luciferase mRNA expression at 6 hr after transfection by 
Bare-PEG2000 lipoplexes, Man-PEG2000 lipoplexes, Bare-PEG2000 bubble lipoplexes with US 
exposure and Man-PEG2000 bubble lipoplexes with US exposure (50 μg pDNA).  ** p < 0.01, 
compared with the corresponding group of CD11c
-
 cells.  Each value represents the mean + 
SD (n = 4). 
 
Fig. 7.  Tissue distribution of pDNA by Man-PEG2000 bubble lipoplexes and US exposure.  
Tissue distribution after intravenous administration of (A) Bare-PEG2000 bubble lipoplexes 
and (B) Man-PEG2000 bubble lipoplexes (50 μg pDNA) with or without US exposure in mice.  
US was exposed at 5 min after intravenous administration of bubble lipoplexes.  Each value 
represents the mean ± SD (n = 3).  * p < 0.05; ** p < 0.01, compared with the corresponding 
group of -US exposure. 
 
Fig. 8.  Liver toxicity by gene transfection using Man-PEG2000 bubble lipoplexes and US 
exposure.  Time-course of serum transaminase activities after transfection by Bare-PEG2000 
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lipoplexes, Man-PEG2000 lipoplexes, Bare-PEG2000 bubble lipoplexes with US exposure and 
Man-PEG2000 bubble lipoplexes with US exposure (50 μg pDNA).  Alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) in the serum were measured at predetermined 
times after transfection.  Each value represents the mean ± SD (n = 4). 
 
Fig. 9.  Cytokine secretion characteristics and CTL activities by DNA vaccination using 
Man-PEG2000 bubble lipoplexes and US exposure.  (A) OVA presentation on MHC class I 
molecules in the splenic CD11c
+
 cells at 24 hr after transfection by Bare-PEG2000 lipoplexes, 
Man-PEG2000 lipoplexes, Bare-PEG2000 bubble lipoplexes with US exposure and Man-PEG2000 
bubble lipoplexes with US exposure (50 μg pDNA).  OVA presentation on MHC class I 
molecules was determined by IL-2 level secreted from CD8-OVA1.3 cells co-incubated with 
the CD11c
+
 cells isolated from once-immunized mice.  Each value represents the mean ± SD 
(n = 4).  * p < 0.05; ** p < 0.01, compared with the corresponding group of N.T..  (B) 
Schedule of immunization for OVA-specific cytokine secretion experiments and CTL assay.  
(C) OVA-specific IFN- and IL-4 secretion from the splenic cells immunized three times 
biweekly by Bare-PEG2000 lipoplexes, Man-PEG2000 lipoplexes, Bare-PEG2000 bubble 
lipoplexes with US exposure and Man-PEG2000 bubble lipoplexes with US exposure (50 μg 
pDNA).  The splenic cells were collected at 2 weeks after last immunization.  After the 
immunized splenic cells were cultured for 72 hr in the absence or presence of 100 μg OVA, 
IFN- and IL-4 secreted in the medium were measured by ELISA.  Each value represents the 
mean + SD (n = 4).  ** p < 0.01, compared with the corresponding group of -OVA.  (D) 
OVA-specific CTL activities after immunization three times by Bare-PEG2000 lipoplexes, 
Man-PEG2000 lipoplexes, Bare-PEG2000 bubble lipoplexes with US exposure and Man-PEG2000 
bubble lipoplexes with US exposure (50 μg pDNA).  CTL activities to E.G7-OVA and EL4 
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cells in the immunized splenic cells were determined by 
51
Cr release assay.  Each value 
represents the mean ± SD (n = 4).  * p < 0.05; ** p < 0.01, compared with the corresponding 
group of N.T..  N.T., non-treatment. 
 
Fig. 10.  Anti-tumor effects by DNA vaccination using Man-PEG2000 bubble lipoplexes and 
US exposure.  (A) Schedule of immunization for experiments of therapeutic effects.  (B, C) 
Anti-tumor effects by immunization using Bare-PEG2000 lipoplexes, Man-PEG2000 lipoplexes, 
Bare-PEG2000 bubble lipoplexes with US exposure and Man-PEG2000 bubble lipoplexes with 
US exposure (50 μg pDNA).  Two weeks after last immunization, (B) E.G7-OVA cells or 
(C) EL4 cells (1 × 10
6
 cells) were transplanted subcutaneously into the back of mice (n = 
8-11).  The tumor volume was evaluated (each value represents the mean ± SD) and the 
survival was monitored up to 80 days after the tumor transplantation.  * p < 0.05; ** p < 0.01, 
compared with the corresponding group of N.T..  N.T., non-treatment. 
 
Fig. 11.  Maintenance of Anti-tumor effects by DNA vaccination using Man-PEG2000 bubble 
lipoplexes and US exposure.  At 80 days after first transplantation of E.G7-OVA cells to 
immunized mice three times by Man-PEG2000 bubble lipoplexes and US exposure, E.G7-OVA 
cells (1 × 10
6
 cells) were re-transplanted subcutaneously into the back of mice which the first 
transplanted tumors were completely rejected (n = 5).  The tumor volume was evaluated 
(each value represents the mean ± SD) and the survival was monitored up to 80 days after the 
tumor re-transplantation.  * p < 0.05; ** p < 0.01, compared with the corresponding group of 
N.T..  N.T., non-treatment. 
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Supplementary Fig. 1.  The cellular association of pDNA obtained by Bare-PEG2000 lipoplexes and 
Man-PEG2000 lipoplexes in mouse cultured macrophages.  (A) Time-course of the cellular association of 
pDNA obtained by Bare-PEG2000 lipoplexes and Man-PEG2000 lipoplexes constructed with 
32P-labeled 
pDNA (5 µg pDNA).  Each value represents the mean ± SD (n = 3).  * p < 0.05; ** p < 0.01, compared 
with the corresponding group of Bare-PEG2000 lipoplex.  (B) Cellular association of pDNA obtained by 
Bare-PEG2000 lipoplexes and Man-PEG2000 lipoplexes constructed with 
32P-labeled pDNA (5 µg pDNA) in 
the absence or presence of 1 mg/mL mannan at 2 hr after addition of each lipoplex.  Each value represents 
the mean + SD (n = 3).  ** p < 0.01, compared with the corresponding group of -mannan.  (C) Inhibition 
of cellular association of pDNA obtained by Bare-PEG2000 lipoplexes and Man-PEG2000 lipoplexes 
constructed with 32P-labeled pDNA (5 µg pDNA) in addition of various endocytosis inhibitors at 2 hr after 
addition of each lipoplex.  Each value represents the mean + SD (n = 3).  ** p < 0.01, compared with the 



































































































































































































































Supplementary Fig. 2.  DNase I protection assay.  Naked pDNA, Bare-PEG2000 lipoplexes and 
Man-PEG2000 lipoplexes were treated with DNase I at 37 °C for 15 min, and subjected to agarose gel 
electrophoresis.  The samples were as follows: naked pDNA (lane 1 and 2); Bare-PEG2000 lipoplexes (lane 
3 and 4); Man-PEG2000 lipoplexes (lane 5 and 6); non-treated with DNase I (lane 1, 3 and 5); treated with 
DNase I (lane 2, 4 and 6).  











































































Supplementary Fig. 3.  Photographs of Man-PEG2000 bubble lipoplexes and stability of Bare-PEG2000 
bubble lipoplexes and Man-PEG2000 bubble lipoplexes against nuclease.  (A) Man-PEG2000 bubble 
lipoplexes (right) were prepared by sonication of Man-PEG2000 lipoplexes (left) with supercharged 
perfluoropropane gas.  (B) DNase I protection assay.  Naked pDNA and lipoplexes were treated with 
DNase I, and then subjected to agarose gel electrophoresis.  The samples were as follows: naked pDNA 
(lane 1 and 2); Bare-PEG2000 lipoplex (lane 3 and 7); Bare-PEG2000 bubble lipoplex (lane 4 and 8); 
Man-PEG2000 lipoplex (lane 5 and 9); Man-PEG2000 bubble lipoplex (lane 6 and 10); non-treated with 










































































































































Supplementary Fig. 4.  Enhancement of cellular association of pDNA by Man-PEG2000 bubble lipoplexes 
and US exposure in vitro.  (A) Cellular association of 32P-labeled pDNA by transfection using naked 
pDNA, naked pDNA + BLs with US exposure, Bare-PEG2000 lipoplexes, Bare-PEG2000 bubble lipoplexes 
with US exposure, Man-PEG2000 lipoplexes and Man-PEG2000 bubble lipoplexes with US exposure (5 µg 
pDNA) at 2 hr after addition of each lipoplex.  Each value represents the mean + SD (n = 3).  Significant 
difference; * p < 0.05; **, †† p < 0.01.  (B) Cellular association by Bare-PEG2000 bubble lipoplexes with 
US exposure and Man-PEG2000 bubble lipoplexes with US exposure (5 µg 
32P-labeled pDNA) at 2 hr after 
addition of each lipoplex.  Each value represents the mean + SD (n = 3).  * p < 0.05, compared with the 


























































































   













































































































Supplementary Fig. 5.  The level of luciferase expression by Man-PEG2000 bubble lipoplexes and direct 
US exposure.  Four-week-old ICR female mice received an intravenous injection of 400 µL Man-PEG2000 
bubble lipoplexes using a 26-gauge syringe needle at a dose of 50 µg pDNA.  After injection of 
Man-PEG2000 bubble lipoplexes, mice were operated the abdominal area under anesthesia.  At 5 min after 
injection of Man-PEG2000 bubble lipoplexes, the organ was exposed directly to US using a Sonopore-4000 
sonicator.  US exposure conditions for the liver: frequency, 1.045 MHz; duty, 50%; burst rate, 10 Hz; 
intensity 1.0 W/cm2; time, 2 min by using a 20 mm diameter probe, and for the spleen: frequency, 2.062 
MHz; duty, 50%; burst rate, 10 Hz; intensity 4.0 W/cm2; time, 2 min using a 6 mm diameter probe.  At 6 
hr after injection, mice were sacrificed and their organs collected for each experiment.  The level of 
luciferase expression in the liver and spleen was determined at 6 hr after injection of Man-PEG2000 bubble 
lipoplexes.  Each value represents the mean + SD (n = 4).  * p < 0.05; ** p < 0.01, compared with the 
corresponding group of Man-PEG2000 lipoplex, 
† p < 0.05; †† p < 0.01, compared with the corresponding 
group of non-exposed US in each organ.  ‡‡ p < 0.01, compared with the corresponding group of 












































































































































Supplementary Fig. 6.  Repeated transfection by Man-PEG2000 bubble lipoplexes and US exposure.  (A) 
Time-course of gene expression in the spleen by Man-PEG2000 lipoplexes and Man-PEG2000 bubble 
lipoplexes with US exposure.  Each value represents the mean ± SD (n = 4).  (B, C) The effect of 
transfection interval between first and second transfection on the level of gene expression by repeated 
transfection using (B) Man-PEG2000 lipoplexes and (C) Man-PEG2000 bubble lipoplexes with US exposure 
in the spleen.  Mice were received the second transfection at 3, 7, 10, 14 and 17 days after first 
transfection.  Each value represents the mean + SD (n = 4).  The level of gene expression was 
sequentially decreased after transfection using Man-PEG2000 lipoplexes or Man-PEG2000 bubble lipoplexes 
with US exposure (Supplementary Fig. 6A).  Therefore, it is considered that multiple transfections are 
essential to obtain more effective vaccine effects against cancer.  However, following optimization of 
transfection interval, the levels of gene expression obtained by Man-PEG2000 lipoplexes or Man-PEG2000 
bubble lipoplexes with US exposure in the second transfection were lower than that in first transfection 
when second transfection was performed at 3rd or 7th day after first transfection (Supplementary Figs. 6B 
and 6C).  In this study, the level of gene expression in the second transfection reached to the same level as 
gene expression in the first transfection when second transfection was performed at 14th day after first 
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Supplementary Fig. 7.  Optimization of immunization times by Man-PEG2000 bubble lipoplexes and US 
exposure.  (A) Schedule of optimization of immunization times by Man-PEG2000 bubble lipoplexes (50 µg 
pDNA) and US exposure.  (B) Effects of the immunization times by Man-PEG2000 bubble lipoplexes and 
US exposure on DNA vaccine effects.  Mice were immunized once, twice, three times and four times 
biweekly.  At the immunized day or 2 weeks after last immunization, E.G7-OVA cells (1 × 106 cells) 
were transplanted subcutaneously into the back of mice.  The tumor volume was calculated as follows: 
(long diameter) × (short diameter)2 × 0.50.  Each value represents the mean ± SD (n = 8) and the survival 
was monitored up to 80 days after tumor transplantation (n = 8).  * p < 0.05; ** p < 0.01, compared with 




















































































































Supplementary Table 1.   Particle sizes and zeta potentials of liposomes and lipoplexes.  Each value 
represents the mean ± SD (n = 3). 
 
 
Bare-PEG2000 liposome (DSTAP:DSPC:NH2-PEG2000-DSPE=7:2:1 (mol))
Man-PEG2000 liposome (DSTAP:DSPC:Man-PEG2000-DSPE=7:2:1 (mol))
Bare-PEG2000 lipoplex (DSTAP:DSPC:NH2-PEG2000-DSPE=7:2:1 (mol))
Man-PEG2000 lipoplex (DSTAP:DSPC:Man-PEG2000-DSPE=7:2:1 (mol))






























Supplementary Table 2.   Optimal lipid composition of lipoplexes to enclose US imaging gas stably.  To 
optimize the lipid composition of lipoplexes to enclose US imaging gas (perfluoropropane gas) stably, 
lipoplexes constructed with several types of phospholipids were prepared and evaluated whether US 
imaging gas was enclosed into prepared lipoplexed stably or not.  The enclosing of US imaging gas was 
identified by the cloudiness of lipoplex solution.  The lipid composition of lipoplexes was cationic 
lipid:neutral lipid:Man-PEG2000-DSPE (7:2:1 (molar ratio)), and the charge ratio of pDNA (pCMV-Luc) 
and liposomes was 1.0:2.3 (-:+).  US imaging gas was enclosed as described in Materials and Methods 
section.  +; enclosing US imaging gas stably, -; not enclosing US imaging gas. 
Cationic lipids: 
DSTAP; 1,2-stearoyl-3-trimethylammoniumpropane (18/0 (carbon chain/the number of double bonds), 
saturated, Tm > 50 °C), 
DOTAP; 1,2-dioleoyl-3-trimethylammoniumpropane (18/1, unsaturated, Tm < 0 °C), 
DOTMA; 1,2-di-o-octadecenyl-3-trimethylammonium propane (18/1, unsaturated, Tm < 0 °C). 
Neutral lipids: 
DSPC; 1,2-distearoyl-sn-glycero-3-phosphocholine (18/0, saturated, Tm = 55 °C), 
DPPC; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (16/0, saturated, Tm = 41 °C), 
DOPE; 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (18/1, unsaturated, Tm = -16 °C), 
DOPC; 1,2-dioleoyl-sn-glycero-3-phosphocholine (18/1, unsaturated, Tm = -20 °C). 







































Supplementary Table 3.  Particle sizes and zeta potentials of bubble liposomes and bubble lipoplexes.  













Bare-PEG2000 bubble liposome (DSTAP:DSPC:NH2-PEG2000-DSPE=7:2:1 (mol))
Man-PEG2000 bubble liposome (DSTAP:DSPC:Man-PEG2000-DSPE=7:2:1 (mol))
Bare-PEG2000 bubble lipoplex (DSTAP:DSPC:NH2-PEG2000-DSPE=7:2:1 (mol))
Man-PEG2000 bubble lipoplex (DSTAP:DSPC:Man-PEG2000-DSPE=7:2:1 (mol))
Particle size (nm) Zeta-potential (mV)
Particle sizes and zeta potentials of bubble liposomes and bubble lipoplexes.
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Supplementary Materials and Methods 
Gel electrophoresis of pDNA. 
15 µL of naked pDNA and lipoplexes (1.5 µg pDNA) were incubated with 5 µL DNase I solution (10 
µg/mL in DNase I buffer consisted of 100 mM Tris, 25 mM MgCl2 and 5 mM CaCl2) for 15 min at 37 °C.  
The digestion by DNase I was terminated by addition of 100 mM EDTA (5 µL).  Electrophoresis was 
carried out with 1% agarose gel prepared with 1 × TAE buffer at a constant voltage of 100 V for 30 min.  
The band of DNA was detected by ethidium bromide and visualized using a LAS-3000 imaging system 
(FUJIFILM Co., Tokyo, Japan). 
 
Evaluation of cellular association of pDNA. 
The cultured macrophages were plated on a 12-well culture plate at a density of 5 × 105 cells/3.8 cm2.  
After 72 hr incubation, the macrophages were washed twice with Hank’s balanced salt solution (HBSS, pH 
7.4), and the culture medium was replaced with 1 mL HBSS containing lipoplexes constructed with 
32P-labeled pDNA ([α-32P]-dCTP, PerkinElmer, Inc., MA, USA).  At predetermined time after incubation, 
the solution was immediately removed and the macrophages were washed five times with ice-cold HBSS.  
The macrophages were solubilized with 0.3 M NaOH solution containing 10% Triton X-100, and the 
resultant cell lysates were dissolved in Soluene-350 (PerkinElmer, Inc., MA, USA).  Then, the resultant 
lysates were decolorized with isopropanol and 30% H2O2, and neutralized with 5 N HCl.  The 
radioactivity of 32P-labeled pDNA was measured in scintillation counter (LSA-500, Beckman Coulter, Inc., 
CA, USA) after addition of Clear-Sol I solution.  The protein concentration was determined with a Protein 
Quantification Kit (Dojindo Molecular Technologies, Inc., Tokyo, Japan). 
